Chemotherapy in epithelial ovarian cancer

被引：78

作者：

Pignata, Sandro ^{[1
]}

Cannella, Lucia ^{[1
]}

Leopardo, Davide ^{[1
]}

Pisano, Carmela ^{[1
]}

Bruni, Giovanni Salvatore ^{[1
]}

Facchini, Gaetano ^{[1
]}

机构：

[1] Natl Canc Inst Naples, Dept Urol & Gynecol, Div Med Oncol, I-80131 Naples, Italy

来源：

CANCER LETTERS | 2011年 / 303卷 / 02期

关键词：

Ovarian cancer; Chemotherapy; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; PACLITAXEL-RESISTANT OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAPERITONEAL CISPLATIN; INTERGROUP TRIAL; RANDOMIZED-TRIAL; INTRAVENOUS CHEMOTHERAPY; DOCETAXEL-CARBOPLATIN; 1ST-LINE TREATMENT;

D O I：

10.1016/j.canlet.2011.01.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the most common type of ovarian cancer; usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with a poor prognosis. Treatment of ovarian cancer is based on the integration of surgery and chemotherapy. Chemotherapy plays a major role both in the adjuvant treatment and in the care of patients with advanced disease. Several active drugs have been introduced in the treatment of ovarian cancer in the last decades and novel targets and agents are under evaluation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：73 / 83

页数：11

共 50 条

[1] First line chemotherapy of advanced epithelial ovarian cancer
Lhomme, C.
Even, C.
Morice, P.
Balleyguier, C.
Petrella, M. C.
Gouy, S.
Uzan, C.
Duvillard, P.
Pautier, P.
BULLETIN DU CANCER, 2009, 96 (12) : 1207 - 1213
[2] Chemotherapy in epithelial ovarian cancer
Tazi, Y.
Pautier, P.
Leary, A.
Lhomme, C.
GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2013, 41 (10): : 611 - 616
[3] Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer
Markman, Maurie
GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 241 - 245
[4] First-line Chemotherapy in Epithelial Ovarian Cancer
Bookman, Michael A.
CLINICAL OBSTETRICS AND GYNECOLOGY, 2012, 55 (01) : 96 - 113
[5] Advances in Epithelial Ovarian Cancer Therapy
Kroep, J. R.
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (25) : 3735 - 3740
[6] Maintenance chemotherapy in the management of epithelial ovarian cancer
Markman, Maurie
CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 11 - 17
[7] Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer
Shimokawa, M.
Ohki, M.
Kaku, T.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (04) : 370 - 375
[8] Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer
Hanna, Rabbie K.
Poniewierski, Marek S.
Laskey, Robin A.
Lopez, Micael A.
Shafer, Aaron
Van Le, Linda
Crawford, Jeffrey
Dale, David C.
Gehrig, Paola A.
Secord, Angeles Alvarez
Havrilesky, Laura J.
Lyman, Gary H.
GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 74 - 80
[9] Epithelial Ovarian Cancer
AL-Niaimi, Ahmed N.
Ahmed, Mostafa
Petersen, Chase B.
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2012, 39 (02) : 269 - +
[10] Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer
Teo, Min Y.
Power, Derek G.
Tew, William P.
Lichtman, Stuart M.
ONCOLOGIST, 2012, 17 (11) : 1450 - 1460

← 1 2 3 4 5 →